Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Vivesto

0.13 SEK

-6.56 %

Less than 1K followers

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-6.56 %
-42.42 %
-43.04 %
-43.90 %
-54.83 %
-50.75 %
-72.13 %
-96.60 %
-99.28 %

Vivesto is a pharmaceutical company focused on developing innovative treatments for serious oncology diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Vivesto was founded in 1988 and is headquartered in Uppsala, Sweden.

Read more
Market cap
70.48M SEK
Turnover
127.93K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
22/12
2025

Extraordinary general meeting '25

27/2
2026

Annual report '25

7/5
2026

General meeting '26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Press release11/24/2025, 9:12 AM

Investor Studios: Business update med Vivesto sänds live 15.00

Vivesto
Press release11/24/2025, 7:00 AM

Vivesto holds a live-streamed business update today November 24

Vivesto
Press release11/24/2025, 7:00 AM

Vivesto håller livesänd Business Update idag den 24 november

Vivesto

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/21/2025, 6:40 AM

DNB Carnegie Access: Vivesto: Raising capital – Q3 review

Vivesto
Press release11/20/2025, 10:15 AM

DNB Carnegie Access: Vivesto - Q3 25 - Rapportintervju

Vivesto
Regulatory press release11/20/2025, 7:35 AM

Kallelse till extra bolagsstämma i Vivesto AB

Vivesto
Regulatory press release11/20/2025, 7:35 AM

Notice of Extraordinary General Meeting in Vivesto AB

Vivesto
Regulatory press release11/20/2025, 7:30 AM

Vivesto beslutar om en fullt säkerställd företrädesemission om cirka 53,8 MSEK villkorat av godkännande från extra bolagsstämma

Vivesto
Regulatory press release11/20/2025, 7:30 AM

Vivesto resolves on a fully secured rights issue of approximately SEK 53.8 million, subject to approval by an Extraordinary General Meeting

Vivesto
Regulatory press release11/20/2025, 7:00 AM

Delårsrapport för perioden 1 januari – 30 september 2025

Vivesto
Press release11/12/2025, 7:00 AM

Vivesto bjuder in till livesänd Business Update den 24 november

Vivesto
Press release11/12/2025, 7:00 AM

Vivesto to hold live-streamed business update on November 24

Vivesto
Press release11/10/2025, 6:02 AM

DNB Carnegie Access: Vivesto: Positive interim readout from the Paccal Vet study

Vivesto
Regulatory press release11/7/2025, 2:15 PM

Vivesto rapporterar positiva interimsresultat från pilotstudie med Paccal Vet i hundar

Vivesto
Regulatory press release11/7/2025, 2:15 PM

Vivesto reports positive interim results for Paccal Vet pilot study in dogs

Vivesto
Regulatory press release11/7/2025, 9:00 AM

Valberedning utsedd inför Vivestos årsstämma 2026

Vivesto
Regulatory press release11/7/2025, 9:00 AM

Nomination Committee appointed for the Annual General Meeting 2026 in Vivesto

Vivesto
Press release11/5/2025, 11:56 AM

DNB Carnegie Access: Vivesto: Preclinical package strengthened

Vivesto
Press release11/4/2025, 7:00 AM

Vivesto erhåller nya positiva prekliniska resultat för Cantrixil i AML

Vivesto
Press release11/4/2025, 7:00 AM

Vivesto receives positive new Cantrixil preclinical results in AML

Vivesto
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.